tetano
Editor, Senior Moderator
J Clin Med
. 2022 Sep 6;11(18):5261.
doi: 10.3390/jcm11185261.
The Potential Impact of Heparanase Activity and Endothelial Damage in COVID-19 Disease
Elisabeth Zechendorf[SUP] 1 [/SUP], Katharina Schröder[SUP] 1 [/SUP], Lara Stiehler[SUP] 1 [/SUP], Nadine Frank[SUP] 1 [/SUP], Christian Beckers[SUP] 1 [/SUP], Sandra Kraemer[SUP] 1 [/SUP], Michael Dreher[SUP] 2 [/SUP], Alexander Kersten[SUP] 2 [/SUP], Christoph Thiemermann[SUP] 3 [/SUP], Gernot Marx[SUP] 1 [/SUP], Tim-Philipp Simon[SUP] 1 [/SUP], Lukas Martin[SUP] 1 [/SUP]
Affiliations
Abstract
SARS-CoV-2 was first detected in 2019 in Wuhan, China. It has been found to be the most pathogenic virus among coronaviruses and is associated with endothelial damage resulting in respiratory failure. Determine whether heparanase and heparan sulfate fragments, biomarkers of endothelial function, can assist in the risk stratification and clinical management of critically ill COVID-19 patients admitted to the intensive care unit. We investigated 53 critically ill patients with severe COVID-19 admitted between March and April 2020 to the University Hospital RWTH Aachen. Heparanase activity and serum levels of both heparanase and heparan sulfate were measured on day one (day of diagnosis) and day three in patients with COVID-19. The patients were classified into four groups according to the severity of ARDS. When compared to baseline data (day one), heparanase activity increased and the heparan sulfate serum levels decreased with increasing severity of ARDS. The heparanase activity significantly correlated with the lactate concentration on day one (r = 0.34, p = 0.024) and on day three (r = 0.43, p = 0.006). Heparanase activity and heparan sulfate levels correlate with COVID-19 disease severity and outcome. Both biomarkers might be helpful in predicting clinical course and outcomes in COVID-19 patients.
Keywords: ARDS; COVID-19; biomarker; endothelial dysfunction; heparan sulfate; heparanase.
. 2022 Sep 6;11(18):5261.
doi: 10.3390/jcm11185261.
The Potential Impact of Heparanase Activity and Endothelial Damage in COVID-19 Disease
Elisabeth Zechendorf[SUP] 1 [/SUP], Katharina Schröder[SUP] 1 [/SUP], Lara Stiehler[SUP] 1 [/SUP], Nadine Frank[SUP] 1 [/SUP], Christian Beckers[SUP] 1 [/SUP], Sandra Kraemer[SUP] 1 [/SUP], Michael Dreher[SUP] 2 [/SUP], Alexander Kersten[SUP] 2 [/SUP], Christoph Thiemermann[SUP] 3 [/SUP], Gernot Marx[SUP] 1 [/SUP], Tim-Philipp Simon[SUP] 1 [/SUP], Lukas Martin[SUP] 1 [/SUP]
Affiliations
- PMID: 36142913
- DOI: 10.3390/jcm11185261
Abstract
SARS-CoV-2 was first detected in 2019 in Wuhan, China. It has been found to be the most pathogenic virus among coronaviruses and is associated with endothelial damage resulting in respiratory failure. Determine whether heparanase and heparan sulfate fragments, biomarkers of endothelial function, can assist in the risk stratification and clinical management of critically ill COVID-19 patients admitted to the intensive care unit. We investigated 53 critically ill patients with severe COVID-19 admitted between March and April 2020 to the University Hospital RWTH Aachen. Heparanase activity and serum levels of both heparanase and heparan sulfate were measured on day one (day of diagnosis) and day three in patients with COVID-19. The patients were classified into four groups according to the severity of ARDS. When compared to baseline data (day one), heparanase activity increased and the heparan sulfate serum levels decreased with increasing severity of ARDS. The heparanase activity significantly correlated with the lactate concentration on day one (r = 0.34, p = 0.024) and on day three (r = 0.43, p = 0.006). Heparanase activity and heparan sulfate levels correlate with COVID-19 disease severity and outcome. Both biomarkers might be helpful in predicting clinical course and outcomes in COVID-19 patients.
Keywords: ARDS; COVID-19; biomarker; endothelial dysfunction; heparan sulfate; heparanase.